Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALZN

ALZN - Alzamend Neuro, Inc. Stock Price, Fair Value and News

0.86USD-0.04 (-4.44%)Delayed as of 21 Feb 2024, 01:46 pm ET
Watchlist

Market Summary

USD0.86-0.04
Delayedas of 21 Feb 2024, 01:46 pm
-4.44%

ALZN Stock Price

View Fullscreen

ALZN RSI Chart

ALZN Valuation

Market Cap

6.4M

Price/Earnings (Trailing)

-0.42

Price/Free Cashflow

-0.72

ALZN Price/Earnings (Trailing)

ALZN Profitability

Return on Equity

-24.19%

Return on Assets

-1.5K%

Free Cashflow Yield

-138.15%

ALZN Fundamentals

ALZN Earnings

Earnings (TTM)

-15.2M

Earnings Growth (Yr)

6.56%

Earnings Growth (Qtr)

17.62%

Breaking Down ALZN Revenue

52 Week Range

0.190.90
(Low)(High)

Last 7 days

-7.6%

Last 30 days

-12.4%

Last 90 days

-49.7%

Trailing 12 Months

39.3%

How does ALZN drawdown profile look like?

ALZN Financial Health

Current Ratio

0.27

ALZN Investor Care

Buy Backs (1Y)

92.62%

Tracking the Latest Insider Buys and Sells of Alzamend Neuro, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 23, 2024
ault milton c iii
sold
-
-
-661,168
-
Jan 05, 2024
ault milton c iii
bought
5,092
1.0185
5,000
-
Dec 26, 2023
ault milton c iii
bought
450
0.9
500
-
Dec 22, 2023
ault milton c iii
bought
184
0.9242
200
-
Sep 26, 2023
katzoff david j
bought
10,234
0.1931
53,000
chief financial officer
May 24, 2023
ault milton c iii
bought
10,704
0.5947
18,000
-
Apr 28, 2023
jackman stephan
bought
19,998
0.5405
37,000
chief executive officer
Mar 22, 2023
mcgrath lynne fahey
bought
4,350
0.435
10,000
-
Mar 17, 2023
ault milton c iii
bought
2,149
0.4298
5,000
-
Mar 16, 2023
ault milton c iii
bought
2,005
0.5014
4,000
-

1–10 of 50

Which funds bought or sold ALZN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-6,673
-
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-6,548
-
-%
Feb 14, 2024
VANGUARD GROUP INC
sold off
-100
-482,355
-
-%
Feb 14, 2024
VANGUARD GROUP INC
new
-
69,905
69,905
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
new
-
42.00
42.00
-%
Feb 14, 2024
STATE STREET CORP
sold off
-100
-7,560
-
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
new
-
2,951
2,951
-%
Feb 13, 2024
RENAISSANCE TECHNOLOGIES LLC
new
-
9,000
9,000
-%

1–10 of 43

Are Funds Buying or Selling ALZN?

Are funds buying ALZN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALZN
No. of Funds

Unveiling Alzamend Neuro, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 02, 2024
ault milton c iii
40.3%
3,158,036
SC 13D/A
Jan 25, 2024
ault milton c iii
29.4%
1,938,036
SC 13D/A
Nov 15, 2022
ault milton c iii
43.2%
43,821,652
SC 13D/A
Apr 28, 2022
ault milton c iii
43.2%
42,368,318
SC 13D/A

Recent SEC filings of Alzamend Neuro, Inc.

View All Filings
Date Filed Form Type Document
Feb 02, 2024
SC 13D/A
13D - Major Acquisition
Feb 02, 2024
8-K
Current Report
Feb 02, 2024
4
Insider Trading
Jan 25, 2024
SC 13D/A
13D - Major Acquisition
Jan 25, 2024
4
Insider Trading
Jan 09, 2024
4
Insider Trading
Jan 05, 2024
8-K
Current Report
Dec 27, 2023
4
Insider Trading
Dec 15, 2023
10-Q
Quarterly Report
Nov 16, 2023
8-K
Current Report

Peers (Alternatives to Alzamend Neuro, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Alzamend Neuro, Inc. News

Latest updates
Benzinga10 Jan 202408:00 am
Business Wire3 months ago

Alzamend Neuro, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Assets-62.6%9842,6285,9168,50210,42512,21014,51612,42914,50116,8182,9132,6382,3632,0891,814
  Current Assets-67.6%7822,4145,8368,41710,33412,11514,41412,42914,50116,8182,913---1,814
    Cash Equivalents-88.2%2001,6955,1417,3769,18311,52714,06411,79013,57315,6181,92941.006.0063.0090.00
  Net PPE-5.9%20221480.0085.0090.0096.00103--------
Liabilities33.8%3,6662,7412,8702,6421,6371,0291,1651,0991,032966900----
  Current Liabilities---2,8702,6421,6371,0291,1654671,4751,473900---992
Shareholder's Equity0.5%62,70062,3703,0465,8608,78711,18213,35211,96213,02515,3442,01329,15628,66726.00822
  Retained Earnings-6.1%-50,506-47,600-44,072-40,767-35,341-32,231-29,194-25,325-22,752-19,152-16,832----11,785
  Additional Paid-In Capital0.5%62,70062,36162,00161,50059,00358,28757,42052,16250,65249,37133,722---27,584
Shares Outstanding-93.3%6,47096,940-96,428-97,48295,482-88,14986,88867,430-72,26372,26364,763
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations54.1%-1,513-3,298-2,235-1,806-2,344-2,536-1,562-1,782-2,046-1,222-1,257-806-442-205-
  Share Based Compensation-13.8%3183694911,5087168671,2581,1311,280740297575654506-
Cashflow From Investing100.0%--147-----------101-
Cashflow From Financing-------3,942400*700*14,9123,14684138677.00-

ALZN Income Statement

2023-10-31
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended6 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2023
Oct. 31, 2022
OPERATING EXPENSES    
Research and development$ 1,996,783$ 1,532,985$ 4,362,920$ 2,908,940
General and administrative904,9391,573,4182,064,7323,233,005
Total operating expenses2,901,7223,106,4036,427,6526,141,945
Loss from operations(2,901,722)(3,106,403)(6,427,652)(6,141,945)
OTHER EXPENSE, NET    
Interest expense(4,311)(3,588)(6,147)(5,120)
Total other expense, net(4,311)(3,588)(6,147)(5,120)
NET LOSS$ (2,906,033)$ (3,109,991)$ (6,433,799)$ (6,147,065)
Basic net loss per common share$ (0.44)$ (0.48)$ (0.98)$ (0.95)
Diluted net loss per common share$ (0.44)$ (0.48)$ (0.98)$ (0.95)
Basic weighted average common shares outstanding6,563,7846,499,2306,563,2306,499,008
Diluted weighted average common shares outstanding6,563,7846,499,2306,563,2306,499,008

ALZN Balance Sheet

2023-10-31
Condensed Balance Sheets (Unaudited) - USD ($)
Oct. 31, 2023
Apr. 30, 2023
CURRENT ASSETS  
Cash$ 200,079$ 5,140,859
Prepaid expenses and other current assets581,802447,589
Prepaid expenses - related party247,334
TOTAL CURRENT ASSETS781,8815,835,782
Property, plant and equipment, net201,71679,843
TOTAL ASSETS983,5975,915,625
CURRENT LIABILITIES  
Accounts payable and accrued liabilities3,666,0902,870,122
TOTAL LIABILITIES, ALL CURRENT3,666,0902,870,122
STOCKHOLDERS’ (DEFICIT) EQUITY  
Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil 0 issued and outstanding as of October 31, 2023 and April 30, 2023
Common stock, $0.0001 par value: 300,000,000 shares authorized; 6,469,657 and 6,462,675 issued and outstanding as of October 31, 2023 and April 30, 2023, respectively647646
Additional paid-in capital62,699,61462,000,814
Note receivable for common stock – related party(14,876,293)(14,883,295)
Accumulated deficit(50,506,461)(44,072,662)
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY(2,682,493)3,045,503
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY$ 983,597$ 5,915,625
ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
 CEO
 WEBSITEwww.alzamend.com
 EMPLOYEES4

Alzamend Neuro, Inc. Frequently Asked Questions


What is the ticker symbol for Alzamend Neuro, Inc.? What does ALZN stand for in stocks?

ALZN is the stock ticker symbol of Alzamend Neuro, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alzamend Neuro, Inc. (ALZN)?

As of Tue Feb 20 2024, market cap of Alzamend Neuro, Inc. is 6.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALZN stock?

You can check ALZN's fair value in chart for subscribers.

What is the fair value of ALZN stock?

You can check ALZN's fair value in chart for subscribers. The fair value of Alzamend Neuro, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alzamend Neuro, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALZN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alzamend Neuro, Inc. a good stock to buy?

The fair value guage provides a quick view whether ALZN is over valued or under valued. Whether Alzamend Neuro, Inc. is cheap or expensive depends on the assumptions which impact Alzamend Neuro, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALZN.